WO1992017209A1 - Porous solid preparation containing physiologically active protein substance - Google Patents
Porous solid preparation containing physiologically active protein substance Download PDFInfo
- Publication number
- WO1992017209A1 WO1992017209A1 PCT/JP1992/000420 JP9200420W WO9217209A1 WO 1992017209 A1 WO1992017209 A1 WO 1992017209A1 JP 9200420 W JP9200420 W JP 9200420W WO 9217209 A1 WO9217209 A1 WO 9217209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid preparation
- collagen
- range
- water
- present
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 95
- 239000007787 solid Substances 0.000 title claims abstract description 66
- 239000000126 substance Substances 0.000 title claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 title abstract description 12
- 108090000623 proteins and genes Proteins 0.000 title abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 48
- 102000008186 Collagen Human genes 0.000 claims abstract description 48
- 229920001436 collagen Polymers 0.000 claims abstract description 47
- 239000000654 additive Substances 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 29
- 229940079322 interferon Drugs 0.000 claims description 22
- 102000014150 Interferons Human genes 0.000 claims description 21
- 108010050904 Interferons Proteins 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 21
- 230000000975 bioactive effect Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000138 intercalating agent Substances 0.000 claims 1
- 229960005188 collagen Drugs 0.000 description 40
- 239000000243 solution Substances 0.000 description 29
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010010803 Gelatin Proteins 0.000 description 10
- 108010045569 atelocollagen Proteins 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- -1 5-interferon Proteins 0.000 description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002197 Sodium polyaspartate Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 108010050934 polyleucine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- the present invention relates to a solid oral or oral administration solid preparation characterized by containing collagen, a water-soluble additive and a proteinaceous physiologically active substance as an active ingredient, and being porous and having good disintegration properties. It concerns the manufacturing method. Background technology With the development of biotechnologies such as genetic recombination and cell culture, large quantities of protein bioactive substances such as cytokines and protein hormones are produced, and are treated in the fields of medicine, animal husbandry, etc. Alternatively, it is being developed or is being developed for diagnostic use. These proteinaceous physiologically active substances generally have poor absorption in the digestive tract and are conventionally administered as injections.
- HIV-1 human immunodeficiency virus type 1
- AIDS AIDS
- WO 8 8 Z 0 3 4 1 1 describes a method of contacting Interfuron with the oral cavity and pharyngeal mucosa c
- the present invention is directed to the treatment by oral or oral dosage forms.
- the present invention relates to a stable solid preparation that releases a protein bioactive substance in a required amount and over a time required for treatment, and a method for producing the same. More specifically, the present invention relates to an oral or oral preparation characterized by being porous and having good degradability, comprising collagen, a water-soluble additive and a proteinaceous bioactive substance as an active ingredient.
- solid dosage form for administration and its manufacturing method
- the present invention relates to an AIDS therapeutic agent or an AIDS progress inhibitor when it contains interferon as a proteinaceous bioactive substance.
- FIG. 1 shows the time course of interfacial release from the sponge-like solid preparation of the present invention (Example 1).
- Figure 2 shows the time course of I Ntafuyuron release from collagen needle Perez Bok Comparative Example 1 As a control c
- the present invention relates to collagen, water-soluble additives and activities.
- the present invention relates to a solid preparation for oral or oral administration characterized by being porous and having good disintegrability, which contains a proteinaceous physiologically active substance as a component and a method for producing the same.
- Collagen examples of “collagen” that can be used in the solid preparation of the present invention include, for example, atelocollagen excluding telopeptid, which is an antigenic site of naturally occurring collagen, collagen obtained by chemically modifying atelocollagen, and naturally occurring collagen. And the like.
- collagen obtained by chemically modifying atelocollagen include succinylated collagen, methylated collagen and the like.
- naturally-derived collagen examples include collagen derived from porcine skin, porcine tendon, pig intestine, hidge intestine, and human placenta.
- the “water-soluble additive” used in the solid preparation of the present invention may be any commonly used water-soluble pharmaceutical additive. Examples thereof include proteins, glycoproteins, amino acids, and poly (amino acid). Examples include amino acids, peptides, saccharides, water-soluble polysaccharides, and the like, or combinations thereof. Examples of proteins include gelatin, albumin, and the like.
- glycoproteins include globulin.
- amino acids include aspartic acid, arginine, glycine, leucine and the like.
- polyamino acids and peptides include polyalanine, polyglycine, sodium polyglutamate, sodium polyaspartate, polylysine, and polyleucine.
- Sugars, polysaccharides, and water-soluble polysaccharides include, for example, fructose, sucrose, lactose, dextran, cyclodextrin, mannitol, sorbitol, and the like.
- Proteinaceous bioactive substance examples include simple proteins, complex proteins, inducible proteins, and the like. Specific examples include cytokines having an immunomodulatory activity, endocrine-related substances, and proteins. Sex hormones, growth factors, nutritional factors, enzymes, etc. Examples include interferon, interleukin, colony stimulating factor, and macrophage activating factor. Examples of the interferon include one interferon, 5-interferon, and interferon. Interleukins include, for example, interleukin-11, interleukin-12, etc.
- c- colony stimulating factors include, for example, pluripotent colony stimulating factor (nrnliti-CSF), granulocyte-monocytic macrophage colony Stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), monocyte macrophage colony stimulating factor (M-CSF) and the like.
- pluripotent colony stimulating factor nrnliti-CSF
- GM-CSF granulocyte-monocytic macrophage colony Stimulating factor
- G-CSF granulocyte colony stimulating factor
- M-CSF monocyte macrophage colony stimulating factor
- the proteinaceous physiologically active substance used in the solid preparation of the present invention includes, for example, a substance extracted from a living body, a synthetic substance, a genetically modified substance, a substance obtained from cell culture, and the like, regardless of the production method.
- proteinaceous physiologically active substance used in the solid preparation of the present invention commercially available products may be usually used.
- Commercially available proteinaceous physiologically active substances generally contain additives and the like.
- the proteinaceous physiologically active substance used in the solid preparation of the present invention may contain the above-mentioned additives.
- the additive include, for example, when the proteinaceous physiologically active substance is interferon, for example, human serum albumin, amino acid, sodium chloride and the like.
- a colony stimulating factor for example, there are saccharides, sugar alcohols, polyethylene glycol and the like.
- interleukin there are, for example, phosphate buffer and human serum albumin.
- composition may contain a pharmaceutical excipient as needed.
- “Pharmaceutical additives” that may be included as needed include commonly used pharmaceutical additives, such as stabilizers, preservatives, buffers, sweeteners, flavoring agents, binders, and suspending agents. And disintegrants.
- Examples of the stabilizer include stabilizers for proteinaceous physiologically active substances, and specific examples include albumin, gelatin, mannitol, and trehalose.
- Examples of the preservative include paraoxybenzoic acid esters, sorbic acid, salicylic acid, and the like.
- Examples of the buffer include a citrate buffer, an acetate buffer, a phosphate buffer and the like.
- Examples of the sweetener include mannitol, darcose, maltose, starch, lactose and the like. ⁇
- As a flavoring agent For example, aspartic acid, cunic acid, lactic acid and the like can be mentioned.
- Examples of the binder include methylcellulose, ethylcellulose, carboxymethylcellulose and the like.
- Examples of the suspending agent include Tween 20 and Tween 80.
- Disintegrators include, for example, glycerin, starch and the like.
- Porous refers to a state in which the drug product has pores and voids.
- the solid preparation of the present invention comprises a low-density porous collagen matrix. That is, the solid preparation of the present invention is a preparation in which collagen matrix has continuous pores, and its shape is, for example, a film shape, a sponge shape, or the like.
- the solid preparation of the present invention can have a density of, for example, 0.1 mg / cm s to 1 g / cm 3 .
- range of 1 0 mg / cm 3 ⁇ 5 0 0 mg / cm 3 is exemplified et al is in the range of 2 0 mg / cin 3 ⁇ 2 0 0 rag / cm 3 can be cited more specifically, More specifically, the range is, for example, 40 mg / cffl 3 to 100 mg / cm 3 .
- the porosity of the solid preparation of the present invention may be, for example, in the range of 99% to 23%. Specifically, the range is 99% to 62%. More specifically, the range is 98% to 85%, and more specifically, the range is 97% to 92%.
- Disintegration refers to the phenomenon in which a formed solid preparation disperses into small particles and dissolves.
- Disintegration time is measured according to the 12th Revised Japanese Pharmacopoeia Disintegration Test Method. Specifically, a tester in which a glass tube with an inner diameter of 21.5 min, an outer diameter of 23.5 mm, and a length of 77.5 ⁇ was fixed was placed in a beaker, and water was used as the test solution. Keep the temperature at 37 ° C. The preparation to be measured is placed in a glass tube, and an auxiliary plate is placed on top of it, and 29 to 32 reciprocations per minute, with an amplitude of 53 M! Move the tester up and down smoothly at ⁇ 57mm. The bottom of the tester has a mesh (mesh opening 2. ⁇ , wire diameter 0.6 mm). The time required for the preparation to be measured by vertical movement to be shaken and disintegrated is the disintegration time.
- the disintegration time of the solid preparation of the present invention may be, for example, within 2 hours. Specifically, the range is 1 minute to 30 minutes, more specifically, the range is 3 minutes to 20 minutes, and most specifically, the range is 5 minutes to 15 minutes.
- oral administration means that the administered preparation disintegrates or dissolves in the gastrointestinal tract such as the esophagus, stomach, and intestine, and dissolves in the gastrointestinal tract wall. The release of a bioactive substance, which comes into contact with the digestive tract wall.
- “Intraoral administration” means that the administered formulation is held in the oral cavity, disintegrates or / and dissolves in the oral cavity, and the proteinaceous bioactive substance is released, and the oral mucosa, pharyngeal mucosa, etc. Say that touches.
- Production method The solid preparation of the present invention can be produced, for example, by the following method.
- a solution of a proteinaceous physiologically active substance, a solution of collagen, and a solution of a water-soluble additive are respectively prepared, and these are mixed. If necessary, a solution of a pharmaceutical additive is added to obtain a uniform mixed solution. Alternatively, a predetermined amount of each component may be added to a solvent to obtain a mixed solution.
- the solvent used to prepare the solution of each substance is, for example, water, a hydrophilic solvent, and preferably water.
- the hydrophilic solvent include alcohol solvents such as methanol and ethanol, and ketones such as acetone. Solvent or a mixed solvent of these with water.
- the concentration of collagen in the mixed solution is usually 5% by weight or less, specifically, in the range of 0.01% to 3% by weight, and more specifically, 0.1% to 2% by weight. %, And most specifically in the range of 0.5% to 2% by weight.
- the concentration of the entire excipient including collagen, water-soluble additives, and optional pharmaceutical additives in the mixed solution is usually 50% by weight or less, and specifically, 0.01% by weight. To 30% by weight, more specifically 0.1% to 20% by weight, and most specifically 2% to 20% by weight.
- Can be The solid preparation of the present invention can be prepared so that the amount of the proteinaceous physiologically active substance per unit dosage of a single administration becomes an amount necessary for treatment of a target disease.
- Proteinaceous bioactive substance is, for example interferon opening down, the amount of proteinaceous bioactive substances per unit formulations administered once when the target disease is AIDS, the range of 1 0 international units to 1 0 5 IU And specifically Is in the range of 10 to 103 international units, and more specifically, in the range of 40 to 400 international units.
- the number of daily administrations is, for example, in the range of once to three times.
- the preparation temperature for mixing each component is in the range of 5 ° C to 30 ° C, and specifically, in the range of 5 ° C to 20 ° C.
- the solution or mixed solution is dried under reduced pressure, concentrated under reduced pressure, and dried under normal pressure to form a shape suitable for treatment.
- drying under reduced pressure include freeze drying under reduced pressure and drying under reduced pressure in a liquid state.
- reduced pressure freeze-drying freeze at a temperature in the range of 140 ° C to 130 ° C and dry under reduced pressure at 10 ° (up to 30 ° C.
- vacuum drying in the liquid state 5 Dry in the range of ° C to 30 ° C.
- the disintegration time of the solid preparation of the present invention can be arbitrarily changed.
- the disintegration time can be adjusted by changing the content ratio of the water-soluble additive in the preparation. Specifically, the disintegration time can be shortened by decreasing the content ratio of the water-soluble additive.
- a formulation having an arbitrary density can be obtained. May be obtained.
- the concentration of the entire excipient in the solution or mixed solution in which each component is uniformly dispersed is 2% by weight to 20% by weight. Within the range.
- the concentration of the entire excipient in a solution or mixture in which each component is uniformly dispersed is reduced to 30% by weight to 50% by weight.
- these obtained solid preparations can be compressed to obtain a solid preparation having a high density and a long disintegration time range.
- the mold for molding the solid preparation of the present invention is not particularly limited, and examples thereof include a stainless steel mold, a resin mold, and a glass mold.
- the shape of the solid preparation of the present invention is not particularly limited, and examples thereof include a sphere, a hemisphere, a needle, a rod, a button, a disk, a film, a tablet, and a capsule.
- dosage forms such as hemispherical, disk-like, and film-like are preferred.
- a dosage form such as a sphere, a tablet and a capsule is preferred.
- the size of the solid preparation of the present invention may be a size suitable for buccal administration and oral administration.
- the diameter is 2 mn! ⁇ 20
- Thickness 0.1mm ⁇ 10Thigh size can range, preferably diameter 5mn! ⁇ 10 marauders, thickness l mn! The size range is up to 5 min.
- oral, film, needle, and tablet preparations If you give 2mn length! It can range in size from ⁇ 2 Omm, preferably 5mn in length! 11 Omm range.
- the diameter is 2 ⁇ ! ⁇ 15mm, thickness 0.
- the size may be in the range of ⁇ 1 Omm, preferably in the range of 5 to 1 Omm in diameter and 1 mm to 3 in thickness.
- the length is 2mn!
- the size can be in the range of 2020 mm, and preferably in the range of 5 mm ⁇ 10 in length.
- a molded sheet is prepared in advance using a PVC sheet used for PTP packaging. If a solution or a mixed solution in which each of the above-mentioned components is uniformly dispersed is poured into the solution, freeze-dried, and sealed with aluminum foil, a molded product packaged in PTP can be obtained.
- the water content of the solid preparation of the present invention after drying is in the range of 20% by weight or less, specifically in the range of 15% by weight or less, and more specifically in the range of 10% by weight or less.
- the solid preparation according to the present invention may be used in an amount of 3 to 10% by weight.
- the agent can be moistened.
- the weight ratio of collagen to the water-soluble additive in the solid preparation of the present invention produced by the above-mentioned production method can be, for example, in the range of 1: 9 to 9: 1-specifically, 1: 9 to 9: 1: The range is 1. Effects of the Invention
- the solid preparation of the present invention is porous, when it is administered into the oral cavity, saliva penetrates into the solid preparation of the present invention through its pores and voids, disintegrating or dissolving the solid preparation. Releases proteinaceous bioactive substances. At the same time, the water-soluble additive dissolves, the collagen matrix is further destroyed and / or dissolved, and the proteinaceous bioactive substance is released.
- the present invention provides a therapeutically effective amount of a proteinaceous bioactive substance by adding a water-soluble additive to collagen and forming it into a porous material, so that the disintegration rate or Z and dissolution rate suitable for oral or oral administration are increased. It provides a solid preparation that can be released at a rapid rate.
- the solid preparation of the present invention has good lyophilizability.
- the solid preparation of the present invention When administered orally, it gradually disintegrates or dissolves in the oral cavity, releasing proteinaceous bioactive substances.
- it disintegrates or dissolves in the gastrointestinal tract such as the esophagus, stomach and small intestine, releasing proteinaceous bioactive substances.
- the solid preparation of the present invention can control the disintegration time and the release rate and release amount of the proteinaceous physiologically active substance. That is, by changing the composition of the solid preparation of the present invention or changing the production method, the release amount and the release time of the therapeutically effective amount of the proteinaceous bioactive substance can be easily changed to a desired value.
- the preparation of the present invention is prepared by mixing each component in a solution state, a uniform preparation can be easily obtained.
- One of the features is that the release of the proteinaceous physiologically active substance is almost constant, and thus the solid preparation of the present invention is particularly suitable for use for therapeutic purposes.
- the solid preparation of the present invention When the solid preparation of the present invention is administered, for example, into the oral cavity, Absorbs and swells to become sticky, which makes it more likely to adhere and retain in the mouth. As described above, since the solid preparation of the present invention can be easily kept in the oral cavity, the proteinaceous physiologically active substance released therefrom can be easily brought into contact with the oral mucosa, the pharyngeal mucosa, etc. for the time required for treatment. it can. The solid preparation of the present invention has less discomfort and irritation.
- the production method of the present invention can be applied to an unstable proteinaceous physiologically active substance, and a solid preparation containing such an active substance can be easily obtained.
- Example 1 120 g of a 2% aqueous atherocollagen solution, 120 g of a 4% gelatin aqueous solution, 2.4 g of sucrose, and 80,000 international units of ⁇ -interfuron were mixed well to obtain a mixed solution containing a single interferon.
- the mixture [rho TP molded sheet (SUMI LI TE R VS S- 1202 , 1 pocket diameter 10 mm, 1 pocket volume 0.351111) in dispensed at 0.3 ml, manufactured by Kyowa Vacuum R 2 L- 30KWS vacuum freeze-drying Lyophilized in a machine. After freeze-drying, the tablets were heat-sealed with aluminum foil and cut into 10 tablets to obtain PTP-packed tablets.
- the resulting tablets contain 100 international units of ⁇ -interferon per tablet.
- the mixture mixture was obtained comprising a non-type inter Der Ron Dispense 0.3 ml each into a PTP molded sheet (SUM ILI TE R VS S—1202, 1 pocket diameter 10 mm, 1 pocket capacity 0.35 ml), and freeze using a Ryosan R2L—30KWS vacuum freeze dryer made by Kyowa Vacuum. Dried. After freeze-drying, tablets were heat-sealed with aluminum foil and cut into 10 tablets to obtain PTP-packed tablets.
- the resulting tablets contain 200 international units of one interface tablet per tablet.
- a solution containing 2 g of epidermal growth factor (EGF) in 0.3 ml, and 12 ml of an aqueous solution containing 3 mg of atelocollagen, 6 mg of gelatin, and 3 mg of lactose were obtained.
- This mixed solution is transferred to a PTP molded sheet (SUM IL I TE R VS S- 1202, 1 pocket diameter of 10, 1 pocket volume 0.35 ml) in dispensed at 0.3 ml, and freeze-dried in the same manner as in Example 1, containing EGF per unit formulation 2 / g A formulation was obtained.
- a solution containing 2 g of epidermal growth factor (EGF) in 0.3 ml, and 12 ml of an aqueous solution containing 3 mg of atelocollagen, 6 mg of gelatin, and 3 mg of lactose were obtained.
- This mixture was treated in the same manner as in Example 4 to obtain a preparation containing 2 g of EGF per unit preparation.
- a solution containing 3 to 200 g, methylated collagen 6 mg, and dextran (40) 6 mg, and an aqueous solution 18 ml containing human serum albumin 3 mg and maltose 3 mg were obtained. This mixture was treated in the same manner as in Example 4 to obtain a preparation containing 200 / zg of GM-CSF per unit preparation.
- a solution containing 1 international unit of human growth hormone in 0.3 ml 12 Oml of an aqueous solution containing 6 mg of hydrolyzed collagen, 3 mg of sodium polyglutamate, 3 mg of glycine, and 3 mg of mannite was obtained. This mixture was treated in the same manner as in Example 4 to obtain a preparation containing 1 international unit of human growth hormone per unit preparation.
- the obtained dried product was cut into a suitable length to obtain a needle-shaped pellet having a diameter of 0.9 mm and containing 100 international units of one interferon per unit preparation.
- the preparation of the present invention can stably retain the active ingredient.
- the present invention is applied to ⁇ -interferon to prepare A storage stability test was performed using the agent (Example 1).
- RIA is a RIA manufactured by Dynabot.
- Table 1 shows the storage stability data obtained using a kit (Interflon-RIA kit) according to a conventional method. From this, the long-term stability of the formulation according to the present invention is expected, Table 1.
- Example 1 3 The formulation of the present invention has good disintegration properties, and when applied to the oral cavity or orally, disintegrates at an appropriate rate to release the active ingredient. .
- Table 2 shows the measurement results or density of the disintegration time of the preparations prepared in the examples. The measurement of the disintegration time is based on the Disintegration Test Method, using water as the test solution, placing an auxiliary plate, and observing the time required for the preparation to disintegrate or dissolve while moving up and down at 37 ° C. did, Table 2 Example Concentration of aqueous solution before drying (%) Percentage of co-gen (%) Density Disintegration time No. Total collagen excipient Colla-gen Z excipient (mg / cm 3 ) (min)
- Example 1 A sponge-form preparation prepared in Example 2 using a collagen needle-shaped pellet prepared according to the method described in Example 1 of JP-A-62-228028 as a control.
- the method for producing the collagen needle pellets described in JP-A-62-228028 is as follows. To 2g of atelocollagen, add 5 ⁇ 1 of an aqueous solution containing desalted Hiichi interphenylon (20 million international units Zml), and refrigerate Let it swell for 20 hours in the refrigerator. Add 1.6 ml of 1N hydrochloric acid and distilled water to make a total volume of 1 Og, and sufficiently dissolve and knead in a mortar to obtain a homogeneous mixture.
- this needle-shaped pellet is prepared by a method different from the method of the present invention in that the needle-shaped pellet is prepared from a solution having a high concentration of collagen as a carrier component.
- test solution PBS buffer containing 0.5% human serum albumin and 0.01% sodium azide
- FIGS. The results are shown in FIGS.
- the vertical axis indicates the release rate (unit:%) of the Nanaichi interface, and the horizontal axis indicates time (unit: minute or day).
- FIG. 1 shows the results of the sponge-form preparation of the present invention (the present invention)
- FIG. 2 shows the results of the collagen needle pellet (control).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930703036A KR100225153B1 (ko) | 1991-04-08 | 1992-04-06 | 단백성 생리학적 활성 물질을 함유하는 다공성 고형 제제 |
BR9205864A BR9205864A (pt) | 1991-04-08 | 1992-04-06 | Formulações sólidas porosas contendo substâncias proteináceas fisiologicamente ativas. |
EP92907987A EP0578823B1 (en) | 1991-04-08 | 1992-04-06 | Porous solid preparation containing physiologically active protein substance |
AT92907987T ATE212235T1 (de) | 1991-04-08 | 1992-04-06 | Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält |
US08/122,430 US5496559A (en) | 1991-04-08 | 1992-04-06 | Porous solid formulations containing proteinaceous physiologically active substances |
DE69232374T DE69232374T2 (de) | 1991-04-08 | 1992-04-06 | Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7499091 | 1991-04-08 | ||
JP7499191 | 1991-04-08 | ||
JP3/74991 | 1991-04-08 | ||
JP3/74990 | 1991-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992017209A1 true WO1992017209A1 (en) | 1992-10-15 |
Family
ID=26416148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000420 WO1992017209A1 (en) | 1991-04-08 | 1992-04-06 | Porous solid preparation containing physiologically active protein substance |
Country Status (8)
Country | Link |
---|---|
US (1) | US5496559A (ja) |
EP (1) | EP0578823B1 (ja) |
KR (1) | KR100225153B1 (ja) |
AT (1) | ATE212235T1 (ja) |
BR (1) | BR9205864A (ja) |
CA (1) | CA2107473A1 (ja) |
DE (1) | DE69232374T2 (ja) |
WO (1) | WO1992017209A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002531394A (ja) * | 1998-11-27 | 2002-09-24 | ▲高▼田 ▲寛▼治 | 消化管用薬物送達経口製剤 |
JP2008114077A (ja) * | 2006-11-06 | 2008-05-22 | Lohmann & Rauscher Gmbh & Co Kg | 口腔領域における炎症、潰傷および/またはアフタを処置するための製品、およびそのような製品の使用 |
JP2009185078A (ja) * | 2001-02-19 | 2009-08-20 | Lts Lohmann Therapie-Systeme Ag | 動物用及びヒト用医薬における活性物質の投与用の、粘膜接着性を有し、崩壊可能な医薬品調合剤 |
JP2011147541A (ja) * | 2010-01-20 | 2011-08-04 | Dainippon Sumitomo Pharma Co Ltd | チューブ内に保持された凍結乾燥製剤 |
JP2020530433A (ja) * | 2017-06-07 | 2020-10-22 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 単位面積質量の大きい急速崩壊性発泡体ウェハ |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122010000050I2 (de) * | 1994-03-02 | 2011-07-21 | Organon Nv | Sublinguales oder bukkales arzneimittel. |
US6270757B1 (en) * | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
CA2134611C (en) * | 1994-10-28 | 2002-12-24 | Richard John Yarwood | Process for preparing solid pharmaceutical dosage forms |
US6099502A (en) * | 1995-04-20 | 2000-08-08 | Acist Medical Systems, Inc. | Dual port syringe |
US6656157B1 (en) | 1995-04-20 | 2003-12-02 | Acist Medical Systems, Inc. | Infinitely refillable syringe |
US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
US6126933A (en) * | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
TW403653B (en) * | 1995-12-25 | 2000-09-01 | Otsuka Pharma Co Ltd | Dry compositions |
AU724689B2 (en) | 1996-05-09 | 2000-09-28 | Pharma Pacific Pty Ltd | Method of treatment |
US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
FR2769505B1 (fr) * | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
SE514342C2 (sv) * | 1999-05-31 | 2001-02-12 | Nobel Biocare Ab | Metod, anordning och användning vid implantat för att tillförsäkra tillförsel av bioaktiv substans till implantatets omgivande ben och/eller vävnad |
US6626862B1 (en) | 2000-04-04 | 2003-09-30 | Acist Medical Systems, Inc. | Fluid management and component detection system |
US20040028738A1 (en) * | 2000-10-05 | 2004-02-12 | Lynn L.H. Huang | Process for the preparation of porous collagen matrix |
US7098315B2 (en) | 2001-01-25 | 2006-08-29 | Nycomed Pharma As | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
MXPA03006687A (es) * | 2001-01-25 | 2004-03-12 | Nycomed Pharma As | Un metodo para preparar una esponja de colageno, un dispositivo para extraer una parte de una espuma de colageno y una de colageno alargada. |
US7052713B2 (en) | 2001-02-13 | 2006-05-30 | Nycomed Pharma As | Carrier with solid fibrinogen and solid thrombin |
EG24184A (en) | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
WO2007011958A2 (en) | 2005-07-15 | 2007-01-25 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
CN102357259A (zh) * | 2011-07-28 | 2012-02-22 | 王珊珊 | 一种生物蛋白海绵及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62230729A (ja) * | 1986-03-31 | 1987-10-09 | Sumitomo Pharmaceut Co Ltd | Csf徐放性製剤 |
JPS63198635A (ja) * | 1987-02-12 | 1988-08-17 | Toray Ind Inc | エイズ原因ウイルスに対する抗ウイルス剤 |
JPH02710A (ja) * | 1988-01-29 | 1990-01-05 | Sumitomo Pharmaceut Co Ltd | コントロールリリース製剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
CA1208558A (en) * | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
JPS6097918A (ja) * | 1983-11-01 | 1985-05-31 | Sumitomo Chem Co Ltd | インタ−フエロン持続性製剤 |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
EP0177342A3 (en) * | 1984-10-04 | 1987-12-02 | Genentech, Inc. | Oral formulation of therapeutic proteins |
DE3688188T2 (de) * | 1985-12-27 | 1993-10-14 | Koken Kk | Verfahren zur Herstellung einer Formulierung mit verzögerter Freisetzung. |
ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
EP0326151B1 (en) * | 1988-01-29 | 1993-06-16 | Sumitomo Pharmaceuticals Company, Limited | Improved controlled release formulation |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
JP3187410B2 (ja) * | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
-
1992
- 1992-04-06 WO PCT/JP1992/000420 patent/WO1992017209A1/ja active IP Right Grant
- 1992-04-06 BR BR9205864A patent/BR9205864A/pt not_active Application Discontinuation
- 1992-04-06 US US08/122,430 patent/US5496559A/en not_active Expired - Fee Related
- 1992-04-06 DE DE69232374T patent/DE69232374T2/de not_active Expired - Fee Related
- 1992-04-06 EP EP92907987A patent/EP0578823B1/en not_active Expired - Lifetime
- 1992-04-06 AT AT92907987T patent/ATE212235T1/de not_active IP Right Cessation
- 1992-04-06 CA CA002107473A patent/CA2107473A1/en not_active Abandoned
- 1992-04-06 KR KR1019930703036A patent/KR100225153B1/ko not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62230729A (ja) * | 1986-03-31 | 1987-10-09 | Sumitomo Pharmaceut Co Ltd | Csf徐放性製剤 |
JPS63198635A (ja) * | 1987-02-12 | 1988-08-17 | Toray Ind Inc | エイズ原因ウイルスに対する抗ウイルス剤 |
JPH02710A (ja) * | 1988-01-29 | 1990-01-05 | Sumitomo Pharmaceut Co Ltd | コントロールリリース製剤 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002531394A (ja) * | 1998-11-27 | 2002-09-24 | ▲高▼田 ▲寛▼治 | 消化管用薬物送達経口製剤 |
JP2009185078A (ja) * | 2001-02-19 | 2009-08-20 | Lts Lohmann Therapie-Systeme Ag | 動物用及びヒト用医薬における活性物質の投与用の、粘膜接着性を有し、崩壊可能な医薬品調合剤 |
JP2008114077A (ja) * | 2006-11-06 | 2008-05-22 | Lohmann & Rauscher Gmbh & Co Kg | 口腔領域における炎症、潰傷および/またはアフタを処置するための製品、およびそのような製品の使用 |
JP2011147541A (ja) * | 2010-01-20 | 2011-08-04 | Dainippon Sumitomo Pharma Co Ltd | チューブ内に保持された凍結乾燥製剤 |
JP2020530433A (ja) * | 2017-06-07 | 2020-10-22 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 単位面積質量の大きい急速崩壊性発泡体ウェハ |
JP2022095893A (ja) * | 2017-06-07 | 2022-06-28 | エルテーエス ローマン テラピー-ジステーメ アーゲー | 単位面積質量の大きい急速崩壊性発泡体ウェハ |
Also Published As
Publication number | Publication date |
---|---|
EP0578823A1 (en) | 1994-01-19 |
DE69232374T2 (de) | 2002-08-29 |
ATE212235T1 (de) | 2002-02-15 |
BR9205864A (pt) | 1994-06-28 |
EP0578823A4 (en) | 1994-12-14 |
CA2107473A1 (en) | 1992-10-09 |
US5496559A (en) | 1996-03-05 |
EP0578823B1 (en) | 2002-01-23 |
KR100225153B1 (ko) | 1999-10-15 |
DE69232374D1 (de) | 2002-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992017209A1 (en) | Porous solid preparation containing physiologically active protein substance | |
KR100852015B1 (ko) | 무젤라틴의 급속 분산성 제형 | |
ES2641821T3 (es) | Forma de dosificación sólida de disolución rápida | |
Nayak et al. | Current developments in orally disintegrating tablet technology | |
RU2242969C2 (ru) | Быстро диспергируемые лекарственные формы, содержащие рыбий желатин | |
JP3122141B2 (ja) | 口腔内溶解型圧縮成型物及びその製造法 | |
RU2445977C2 (ru) | Водорастворимые пленки, содержащие маловязкие альгинаты | |
JPH10502376A (ja) | 新規ドラッグデリバリーシステム | |
TW201422254A (zh) | 用於速釋及延釋的組成物 | |
CA2552677A1 (en) | Controlled release cgrp delivery composition for cardiovascular and renal indications | |
JP2006509771A (ja) | マンノースをベースとした速溶性錠剤 | |
JP2902785B2 (ja) | 迅速溶解経口投与剤 | |
JPWO2005084703A1 (ja) | 徐放性の口腔用組成物 | |
WO2007011958A2 (en) | Intraoral dosage forms of glucagon | |
US20080305139A1 (en) | Pharmaceutical Compositions Comprising Dextran with a Molecular Weight of 1.0-100 Kda and Processes for Their Preparation | |
JPH0995440A (ja) | 徐放性製剤およびその製造方法 | |
Pathak et al. | Buccal drug delivery system: a tool for the effective delivery of pharmaceuticals | |
JP2006523703A (ja) | 吸収ウィンドウ問題を克服するための、活性剤をバッカルまたは舌下の位置から放出する薬学的組成物 | |
Singh et al. | Mouth Dissolving Tablets: An innovative deviation in drug delivery system | |
Patil et al. | Formulation and Evaluation of Mouth Dissolving Tablet | |
Bhagat et al. | Mouth dissolving tablet: A formulation approach | |
Kanade et al. | Review on Sublingual Tablets–A Promising Formulation for Instant Action | |
JPS62152816A (ja) | ゲル状高分子の成形方法 | |
RU2432171C2 (ru) | Иммуностимулирующее лекарственное средство и способ его получения | |
Deshmukh et al. | ORALLY DISINTEGRATING TABLET: AN OVERVIEW |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2107473 Country of ref document: CA Ref document number: 08122430 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992907987 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992907987 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992907987 Country of ref document: EP |